Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Cancer and Oncology
-
3. Latest advances in the development of CAR & TCR T-cell treatments for solid tumours
- Dr. Else Marit Inderberg
-
4. Mode of action of T cells engineered with CAR or TCR for cancer treatment
- Prof. Sebastian Kobold
-
5. Immunotherapy: insights from advanced disease
- Dr. Sara M. Tolaney
-
6. Recent advances in the field of non-coding RNAs in cancer
- Prof. George Calin
- Dr. Maitri Shah
-
7. How tumor-microenvironment interactions drive or inhibit metastasis
- Prof. Isaac P. Witz
-
8. A novel cancer therapy to stimulate oncogenic ERK signalling
- Prof. Reiko Sugiura
-
9. MRD-driven multiple myeloma treatment: next step forward
- Prof. Ola Landgren
-
11. Germinal centre lymphomas: advances in diagnostic and therapeutic intervention
- Dr. Koorosh Korfi
- Prof. Jude Fitzgibbon
-
12. Immunotherapy in lung cancer
- Dr. Mark M. Awad
-
13. Preservation of fertility in cancer patients: the impact of chemotherapy
- Prof. Kutluk H. Oktay
-
15. Solution proposed to a 2000 year old problem in oncology
- Dr. Michael Retsky
- Clinical Practice
-
16. Stillbirth: diagnosis, investigation and aftercare
- Prof. Alexander E. P. Heazell
-
17. Analyzing the medical relevance of skin care trends
- Prof. Zoe Draelos
-
18. Genetic counseling: preconception, prenatal, perinatal
- Prof. Aubrey Milunsky
-
19. The past, present & future of ANA testing: history and challenges of ANA
- Prof. Marvin J. Fritzler
-
20. The past, present & future of ANA testing: changing bandwidth and future of ANA
- Prof. Marvin J. Fritzler
-
22. Mitochondrial diseases: an update
- Dr. Ayesha Saleem
-
23. Hemophilia A
- Dr. Snejana Krassova
-
26. Recent advances in diagnosis and interventions in ophthalmology
- Dr. Rebecca Kaye
- Prof. Andrew Lotery
- Gastroenterology
-
27. Building implantable human liver tissue from pluripotent stem cells
- Prof. David C. Hay
-
28. Microbiome therapies to treat gastrointestinal diseases
- Dr. Patricia Bloom
-
29. Drug-induced liver injury: importance, epidemiology, and mechanisms of DILI
- Prof. James H. Lewis
-
30. Drug-induced liver injury: risk factors and drug development in DILI
- Prof. James H. Lewis
-
31. Drug-induced liver injury: HDS, diagnosing, treating and preventing DILI
- Prof. James H. Lewis
-
32. An update on the multiple faces of celiac disease
- Prof. Aaron Lerner
- Immunology
-
33. Drug allergy: new knowledge
- Prof. Mariana C. Castells
-
34. Biologics as a treatment strategy in food allergy
- Prof. Sayantani B. Sindher
-
35. B cells at the crossroads of autoimmune diseases
- Dr. Xiang Lin
-
36. Studying immune responses “one cell at a time”
- Dr. Mir-Farzin Mashreghi
-
37. Mathematical modeling in immunology
- Prof. Ruy M. Ribeiro
-
38. Therapeutic antibody development
- Prof. Dr. Katja Hanack
-
39. Understanding treatment coverage in mass drug administrations
- Dr. Margaret Baker
-
40. The thymus and T cell development: a primer
- Prof. Georg Holländer
- Infectious Diseases
-
42. The Global Virus Network: collaboration to address pandemic and regional threats
- Prof. Sten H. Vermund
-
43. New concepts in the management of CAP: a focus on severe illness - treatment and therapies
- Prof. Michael S. Niederman
-
44. New concepts in the management of CAP: a focus on severe illness - MRSA and MDR pathogens
- Prof. Michael S. Niederman
-
45. CRISPR-based suppression drives for vector control
- Prof. Andrea Crisanti
-
46. HIV cure: harnessing innate and adaptive strategies
- Prof. Luis Montaner
- Cardiovascular, Metabolism & Nutrition
-
47. Cow’s milk allergy: the future
- Dr. Carina Venter
-
48. Cow's milk allergy: management
- Dr. Carina Venter
-
49. Moving from GWAS hits to functional variants
- Prof. Steve Humphries
-
50. X-linked hypophosphataemia: genetics, diagnosis and management
- Prof. Thomas O. Carpenter
-
51. What is new in type 1 diabetes?
- Prof. Åke Lernmark
-
52. Current concepts for the management of patients with osteoporosis
- Dr. Michael Lewiecki
-
53. Antibodies to control or prevent type 1 diabetes
- Dr. Robert Hilbrands
-
54. Peptide YY (PYY) in obesity and diabetes
- Dr. Nigel Irwin
- Microbiology
-
55. Vaccines and the fight against antimicrobial resistance 1
- Dr. Annaliesa S. Anderson
-
56. Vaccines and the fight against antimicrobial resistance 2
- Dr. Annaliesa S. Anderson
-
57. Vaccines as a weapon against antibiotic resistance
- Dr. Pumtiwitt McCarthy
-
58. PathoLive: pathogen detection while sequencing
- Dr. Simon Tausch
-
60. Successes and failures with vaccines
- Prof. Stanley Plotkin
-
61. Immunology, the microbiome and future perspectives
- Prof. Sheena Cruickshank
-
62. Impact of the HPV vaccine programme – a changing landscape
- Dr. Kevin Pollock
- Neurology and Neuroscience
-
63. Advances in the diagnosis and treatment of tardive dyskinesia
- Prof. Emeritus Stanley N. Caroff
-
64. Cellular therapies for neurological Injuries: bioreactors, potency, and coagulation
- Prof. Charles S. Cox, Jr.
-
65. Cardiovascular involvement in Parkinson’s disease
- Dr. David S. Goldstein
-
66. Molecular brain imaging (PET) in diseases with dementia
- Prof. Karl Herholz
-
67. Current thinking in pain medicine and some thoughts on back pain
- Dr. Nick Hacking
-
68. Bioelectronic medicine: immunomodulation by vagus nerve stimulation
- Prof. Paul Peter Tak
-
69. Developments & future directions in the management of chronic pain
- Prof. Simon Haroutounian
-
70. Deep Brain Stimulation (DBS) neuromodulation for Schizophrenia
- Prof. Judith Gault
-
71. Parkinson’s at 200 years: an update on Parkinson’s research in 2017
- Prof. Patrick A. Lewis
-
72. Alzheimer's disease: where are we up to?
- Prof. John Hardy
- Pharmaceutical Sciences
-
73. Pharmacokinetics, -dynamics and dosing considerations in children
- Prof. Dr. Karel Allegaert
-
74. Why in vitro permeation test – and not in vivo?
- Prof. Howard Maibach
-
75. The future of plasma-derived medicinal products (PDMP)
- Dr. Daniele Focosi
-
76. RNA therapeutics: clinical applications and methods of delivery
- Prof. John P. Cooke
-
77. Recent advances in the development of gene delivery technologies
- Dr. Takis Athanasopoulos
-
78. Preclinical translation of mesenchymal stem cell therapies
- Dr. Peter Childs
-
79. Modulating gene expression to treat diseases
- Dr. Navneet Matharu
-
80. Accelerating drug discovery with machine learning and AI
- Dr. Olexandr Isayev
-
81. AI and big data in drug discovery
- Mr. Ed Addison
-
82. Emerging big data in medicinal chemistry: promiscuity analysis as an example
- Prof. Dr. Jürgen Bajorath
- Dr. Ye Hu
-
83. Binding kinetics in drug discovery
- Dr. Rumin Zhang
-
84. Modeling of antibody-drug conjugate pharmacokinetics
- Dr. Dhaval K. Shah
-
85. Antibody engineering: beginnings to bispecifics and beyond
- Dr. Ian Wilkinson
-
86. Current challenges in the design of antibody-drug conjugates
- Prof. L. Nathan Tumey
-
87. Inorganic nanostructured interfaces for therapeutic delivery
- Prof. Tejal Desai
-
88. Latest development in therapy-related autophagy research
- Dr. Vignir Helgason
- Respiratory Diseases
-
89. Respiratory syncytial virus vaccination
- Prof. Peter Openshaw
-
90. Advances in gene therapy for respiratory diseases 1
- Prof. John F. Engelhardt
-
91. Advances in gene therapy for respiratory diseases 2
- Prof. John F. Engelhardt
-
92. Asthma
- Prof. William Busse
- Dr. Amanda McIntyre
-
93. New drugs for asthma
- Prof. Peter Barnes
-
94. CompEx asthma: a novel composite exacerbation endpoint
- Dr. Carla A. Da Silva
-
95. Updates in chronic obstructive pulmonary disease (COPD)
- Dr. Omar S. Usmani
Printable Handouts
Navigable Slide Index
- Introduction
- Lecture outline
- Multi-step metastasis model
- Part I: EMT and cellular plasticity
- Epithelial cells are connected by various cell junctions
- How do carcinoma cells invade?
- Local invasion – collective invasion
- Local invasion – invasive ductal carcinoma
- Mammary terminal endbud invades stroma
- Local invasion – single cell invasion
- Local invasion – Cajal's drawings
- Local invasion – invasive lobular carcinoma
- Gastrulation
- Neural crest development
- Epithelial-Mesenchymal Transition (EMT)
- Epithelial-mesenchymal plasticity
- How is this program regulated?
- Adherens junction
- Suppression of E-cadherin during EMT
- CDH1 germline mutations in hereditary diffuse gastric cancers (1)
- CDH1 germline mutations in hereditary diffuse gastric cancers (2)
- Loss of cell adhesion in invasive lobular carcinoma
- Cell scattering and invasiveness induced by HGF
- Transcription regulation of EMT
- Snail represses E-cadherin transcription through E-boxes
- Snail in gastrulation
- Snail in neural crest development
- EMT in Drosophila mesoderm formation
- Twist is a potent inducer of EMT
- Twist is essential for breast tumors to metastasize
- EMT: molecular markers summary
- Invadopodia: specialized structures for matrix degradation
- Twist-induced invadopodia is functional in ECM degradation
- Transcription regulation of EMT: main families
- Transcription regulation of EMT: cancer associations
Topics Covered
- Multi-step metastasis model
- Epithelial derived carcinoma
- Collective invasion
- Drosophila gastrulation
- Xenopus neural crest formation
- Epithelial-mesenchymal transition (EMT)
Links
Series:
- The Molecular Basis of Cancer
- Periodic Reports: Advances in Clinical Interventions and Research Platforms
Categories:
Therapeutic Areas:
Talk Citation
Yang, J. (2023, April 30). The molecular basis of cancer metastasis: molecular mechanisms of epithelial-mesenchymal transition in tumor metastasis [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 31, 2024, from https://doi.org/10.69645/LWAU2642.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Jing Yang has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
The molecular basis of cancer metastasis: molecular mechanisms of epithelial-mesenchymal transition in tumor metastasis
Published on April 30, 2023
30 min
A selection of talks on Oncology
Transcript
Please wait while the transcript is being prepared...
0:00
Hello everyone,
Today, my lecture's title is
The Molecular Basis
of Cancer Metastasis.
Let me first introduce myself.
My name is Jing Yang.
I'm a professor at
the University of
California San Diego,
Department of Pharmacology
and Pediatrics.
My lab is at the Moores
Cancer Center at UCSD.
0:22
First, I would like
to introduce you to
the outline of the lecture.
I will first discuss
the multi-step process
of tumor metastasis.
Then I will spend a
significant amount of time
to discuss this
epithelial-mesenchymal transition
and cellular plasticity
in metastasis.
Then we will talk about
organ-tropic metastasis and
how dysregulation in
tropism is regulated.
In the end,
I will have a brief discussion
on how to develop
therapeutics to
prevent or inhibit the
development of metastasis.
0:59
As you all know,
there has been a lot of work
that has been done,
trying to understand
the molecular basis of
primary tumor formation.
But what's really killing
cancer patients is
actually metastasis.
Metastasis is a
multi-step process where
a primary tumor cell set
initially located in
this primary site becomes
locally invasive,
invades through the
basement membrane,
and then makes it to
the nearby tissue.
Some of the tumor cells are
able to intravasate
into the circulation,
enter the blood and
lymphatic circulation.
After surviving in
the circulation,
they are extravasated
from the circulation
into the distant organs.
At the distant organ,
some of the tumor cells are able
to either adapt themselves to
this new microenvironment or
they actually modify
this environment
to make it much more
friendly to themselves.
That allows them to
re-grow to forme
the secondary growths that are
eventually life-threatening
to the patients.
Major research efforts in
the metastasis research
is trying to understand
the molecular and
cellular programs
that are activated to allow
the stationary epithelial cells
to have the ability to migrate,
to invade, and eventually
spread to a distant site.
Hide